Compound Screening Disease Pharma Companies Research 
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Several of the large pharma companies have recently re-entered the dementia field.
Drug Discovery World
JANUARY 26, 2023
DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities.
Expert insights. Personalized for you.
130 
Let's personalize your content